BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rasmussen LD, Bøttcher M, Ivarsen P, Jørgensen HS, Nyegaard M, Buttenschøn H, Gustafsen C, Glerup S, Bøtker HE, Svensson M, Winther S. Association between circulating proprotein convertase subtilisin/kexin type 9 levels and prognosis in patients with severe chronic kidney disease. Nephrology Dialysis Transplantation 2020;35:632-9. [DOI: 10.1093/ndt/gfy257] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Kajingulu FM, Lepira FB, Nkodila AN, Makulo JR, Mokoli VM, Ekulu PM, Bukabau JB, Nlandu YM, Longo AL, Nseka NM, Labriola L, Sumaili EK. Circulating Proprotein Convertase Subtilisin/Kexin type 9 level independently predicts incident cardiovascular events and all-cause mortality in hemodialysis black Africans patients. BMC Nephrol 2022;23:123. [PMID: 35354429 DOI: 10.1186/s12882-022-02748-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Kajingulu FM, Lepira FB, Nkodila AN, Makulo JR, Mokoli VM, Ekulu PM, Bukabau JB, Nlandu YM, Longo AL, Nseka NM, Sumaili EK. Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels Predict Future Cardiovascular Event Risks in Hemodialyzed Black African Patients. Rambam Maimonides Med J 2021;12. [PMID: 34270402 DOI: 10.5041/RMMJ.10443] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zhou Y, Chen W, Lu M, Wang Y. Association Between Circulating Proprotein Convertase Subtilisin/Kexin Type 9 and Major Adverse Cardiovascular Events, Stroke, and All-Cause Mortality: Systemic Review and Meta-Analysis. Front Cardiovasc Med 2021;8:617249. [PMID: 33738300 DOI: 10.3389/fcvm.2021.617249] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
4 Qi Z, Hu L, Zhang J, Yang W, Liu X, Jia D, Yao Z, Chang L, Pan G, Zhong H, Luo X, Yao K, Sun A, Qian J, Ding Z, Ge J. PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36. Circulation 2021;143:45-61. [PMID: 32988222 DOI: 10.1161/CIRCULATIONAHA.120.046290] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 24.5] [Reference Citation Analysis]
5 Hwang HS, Kim JS, Kim YG, Lee SY, Ahn SY, Lee HJ, Lee DY, Lee SH, Moon JY, Jeong KH. Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients. J Clin Med 2020;9:E244. [PMID: 31963408 DOI: 10.3390/jcm9010244] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
6 Panahi Y, Ghahrodi MS, Jamshir M, Safarpour MA, Bianconi V, Pirro M, Farahani MM, Sahebkar A. PCSK9 and atherosclerosis burden in the coronary arteries of patients undergoing coronary angiography. Clin Biochem 2019;74:12-8. [PMID: 31493378 DOI: 10.1016/j.clinbiochem.2019.09.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]